Online inquiry

IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11789MR)

This product GTTS-WQ11789MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11789MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8960MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ6621MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ9153MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ171MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ15242MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TAK-079
GTTS-WQ9424MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ708MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ15007MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW